复方儿茶胶囊联合西沙比利治疗反流性食管炎的疗效

目的：观察复方儿茶胶囊联合西沙比利孤流性食管炎的部效。方法：１７２例反流性食管炎的患者,随机分为治疗及对照组各８６例,治疗组用西沙比利１０ｍｇ,ｑｉｄ,ｐｏ,加复方儿茶胶囊０．５１５,ｔｉｄ,ｐｏ;对照组用西沙比利１０ｍｇ,ｑｉｄ,ｐｏ,每２周复诊１次,４周和８周后再次进行胃镜检查。结果：２组患者治疗后症状总分无明显下降,胃镜下反流性食管炎愈合率对照组和治疗组分别为８０．２％和９３％（Ｐ〈０．０５     

兰索拉唑治疗十二指肠溃疡40例

目的：评价兰索拉唑对十二指肠溃疡的近期疗效。方法：对经胃镜检查确诊的二十指肠溃疡活动期７７例，随机分为两组，治疗组每天晨服兰索拉唑３０ｍｇ，对照组每晚口服西咪替丁８００ｍｇ，疗程４周。结果：治疗愈合率９２．５％，对照组愈合率７５．７％。结论：兰索拉唑治疗十二指肠溃疡的近期疗效可靠。     

兰索拉唑15mg与30mg治疗十二指肠溃疡效果及其安全性比较

为了比较兰索拉唑每日１５ｍｇ与３０ｍｇ两处剂量口服治疗十二指肠溃疡的效果及安全性,对１０９例经内镜证实活动性十二指肠溃疡随机分成１５ｍｇ组（５１例）和３０ｍｇ组（５８例）。剂量分别为每日１５ｍｇ和３０ｍｇ,疗程２￣４周。于疗程结束后重复胃镜检查,２周溃疡愈合率１５ｍｇ组为７０．６％;３０ｍｇ组为８９．７％,３０ｍｇ组明显高于１５ｍｇ组（Ｐ〈０．０５）。４周溃疡愈合率１５ｍｇ和３０ｍｇ组分别为９６．     

奥美拉唑治疗吻合口溃疡的临床观察

为验证奥美拉唑治疗吻合口溃疡的疗效，对经纤维胃镜确诊的消化性溃疡术后发生的吻合口溃疡患者３４例作了观察，全部病人均为活动期溃疡，按确诊时间为序，随机编入奥美拉唑组（治疗组）１８例，雷尼替丁组（对照组）１６例。治疗组服奥美拉唑２０ｍｇ，每晨１次；对照组服雷尼替丁０．１５ｇ，每日２次，疗程４周。于治疗２周末及４周后进行复诊，复诊时记录服药情况、症状缓解的时间及不良反应，于４周末复查胃镜及各项化验指标。结果奥美拉唑组溃疡愈合率９４．４％（１７／１８），雷尼替丁组溃疡愈合率为８７．５％（１４／１６）；治疗组与对照组，３天内疼痛缓解率分别为５６３％（９／１６）和３５７％（５／１４），腹痛缓解率分别为９３８％（１５／１６）和８５７％（１２／１４），总有效率分别为１００％（１８／１８）和８７．５％（１４／１６）。奥美拉唑治疗过程中无明显不良反应，显示奥美拉唑是治疗吻合口溃疡安全效佳的药物。     

西沙比利治疗功能性消化不良50例疗效观察

目的：通过西沙比利和吗丁啉对照治疗功能性消化不良的临床观察,了解西沙比利的临床疗效及不良反应。方法：将确诊的１００例功能性消化不良患者随机分为两组,每组５０例。西沙比利５ｍｇ,每日３次,疗程４周;吗丁啉１０ｍｇ,每日３次,疗程４周。结果：西沙比利组显效３２例（６４％）,有效１２例（１２％）,总有效率为８８％;吗叮啉组显效２５例,有效１０例,总有效率７０％。提示：西沙比利在作用范围、疗效方面优于吗叮啉。     

兰索拉唑每日15mg与每日30mg治疗消化性溃疡的比较

目的：探索兰索拉唑１５ｍｇ／ｄ和３０ｍｇ／ｄ治疗消化性溃疡的比较。方法：６３例经胃镜证实为活动性消化性溃疡病人，随机分成１５ｍｇ／ｄ组３３例，３０ｍｇ／ｄ组３０例，疗程均为４ｗｋ。疗程结束后３ｄ内复查胃镜。结果：用药４ｗｋ胃镜下溃疡愈合率（疤痕期或溃疡消失）１５ｍｇ／ｄ组为８５％，３０ｍｇ／ｄ组为８７％。２组总有效率各为１００％（Ｐ＞０．０５）。服药后中上腹疼痛消失及反酸症状消失，１５ｍｇ／ｄ组与３０ｍｇ／ｄ组依次为５．９±ｓ１．８ｄ，４．５±１．８ｄ与３．２±１．４ｄ，３．０±１．０ｄ。２组差别均有非常显著意义（Ｐ＜０．０１）。结论：口服兰索拉唑１５ｍｇ／ｄ总有效率与口服３０ｍｇ／ｄ相仿，但疼痛和反酸症状消失３０ｍｇ／ｄ组比１５ｍｇ／ｄ组更快     

兰索拉唑治疗十二指肠溃疡

对经胃镜检查确诊的活动期十二指肠溃疡６０例，随机分为２组，试验组（兰索拉唑组）每天晨服兰索拉唑３０ｍｇ，对照组（泰胃美组）每天晚上服泰胃美８００ｍｇ疗程为４周。试验组愈合率和有效率分别为９６．７％和１００％，对照组愈率和有效率分别为７０．０％和８０．０％（Ｐ〈０．０５）；两组疼痛缓解率分别为１００％和７６．９％（Ｐ〈０．０５）。在治疗中未见明显不良反应，本研究表明兰索拉唑治疗十二指肠溃疡优于Ｈ２受     

西沙比利治疗功能性消化不良50例疗效观察

目的 通过西沙比利和吗叮啉对照治疗功能性消化不良的临床观察,了解西沙比利的临床疗效及不良反应,方法 将确诊的１００例功能性消化不良患者随机分为两组,每组５０例,西沙比利５ｍｇ,每日３次,疗程３周,吗丁啉１０ｍｇ每日３次,疗程４周,结果,西沙比利组显效３２例（６４％）,有效１２例（１２％）,总有效率为８８％,吗叮啉组显效２５例,有效１０例,总有效率７０％。提示;西沙比利在作用范围,疗效方面优于吗叮啉     

法莫替丁睡前顿服治疗十二指肠球部溃疡

目的：验证法莫替丁睡前顿服治疗十二指肠部溃疡的疗效。方法：７４例十二指肠溃疡病人分为两组：一次地组３１例,睡前顿服法莫替丁４０ｍｇ;两次疗法组４３例,早、晚各服法莫替丁２０ｍｇ,４周为一疗程。结果：一次疗法组总有效率为９３．５％,两次疗法组总有效率为９５．３％,两组比较经Ｒｉｄｉｔ分析无显著差异。结论：法莫替丁睡前顿服４０ｍｇ治疗十二指肠溃疡疗效可靠,与两次疗法组疗效相近,服药１周内,两组腹痛征状     

0.5%呋喃唑酮混悬液和西咪替丁治疗消化性溃疡疗效观察

目的：观察０．５％呋喃唑酮混悬液和西咪替丁（ＣＭＤ）口服给药治疗消化性溃疡的疗效。方法：２６８例消化性溃疡患者随机分为两组。对照组ＣＭＤ０．３ｇ,每日三餐饭后１５ｍｉｎ口服,晚上睡前加服０．４ｇ;治疗组在服用ＣＭＤ同时加服０．５％呋喃唑酮混悬液５ｍｌ。４周为一疗程。结果：治疗组总有效率９１．８％、溃疡愈合率７８．４％、腹痛缓解率８８．８％和ＨＰ清除率８０．６％,分别高于对照组的７０．１％,５５．２     

瑞巴派特联合法莫替丁治疗活动期胃溃疡61例

目的评估瑞巴派特联合法莫替丁治疗幽门螺杆菌感染的活动期胃溃疡患者溃疡愈合质量。方法采用多中心、随机、开放、阳性药物对照研究设计。120例患者随机分为治疗组与对照组。治疗组用瑞巴派特100 mg,po,tid,法莫替丁片20mg,po,bid;对照组用奥美拉唑胶囊20 mg,每日晨空腹口服。疗程均为6 wk。治疗前后分别行病理组织学检查评估溃疡愈合质量。结果治疗6 wk后,2组患者上腹痛、腹胀、反酸、嗳气等症状均有显著改善(P<0.01)。2组溃疡愈合有效率无显著性差异。2组患者治疗后组织学表现较治疗前显著好转(P<0.01)。治疗组患者中性黏液含量恢复较对照组好(P<0.05)。治疗组发生2例不良反应,对照组无不良反应。治疗组药物费用显著低于对照组,节约治疗费用21.6%。结论瑞巴派特联合法莫替丁治疗伴幽门螺杆菌感染的活动期胃溃疡具有更好的溃疡愈合质量与更少的药物费用。     

Comparison of 40 mg famotidine nightly and 150 mg ranitidine b.d.: ulcer healing and symptom relief in benign gastric ulcer

Two hundred and eight patients with benign gastric ulcers seen on endoscopy were recruited by 13 hospitals in the United Kingdom and Ireland into this double-blind study. Patients were assigned by pre-randomized schedule to 8 weeks of treatment with either 40 mg famotidine at night or 150 mg ranitidine b.d. Repeat endoscopy confirmed complete ulcer healing in 62 of 77 evaluable patients in the famotidine group (81%) and 58 of 71 in the ranitidine group (82%). The treatments were equally effective in promptly relieving day and night pain. Adverse events were uncommon; dizziness and headaches were the most frequently reported in both groups. In conclusion, night-time famotidine is as effective as twice daily ranitidine in healing benign gastric ulcers and provides similarly rapid symptomatic relief.     

Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases

Famotidine is a highly selective histamine H2-receptor antagonist. In healthy volunteers and patients with acid hypersecretory disease it is approximately 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and 8 times more potent than ranitidine on a weight basis. As shown in placebo-controlled trials, famotidine is effective in healing both duodenal and gastric ulcers. Famotidine 20mg twice daily or 40mg at bedtime achieves healing rates and symptom relief similar or superior to those achieved by cimetidine 800mg daily or ranitidine 300mg daily in patients with peptic ulcer disease. Results of 1 placebo-controlled study suggest that famotidine prevents recurrence of duodenal ulcer, but comparative trials are needed to establish its relative efficacy in maintenance therapy. The few non-comparative trials conducted to date also suggest that famotidine 10 to 20mg twice daily may be effective in the treatment of gastritis and reflux gastro-oesophagitis. In comparative trials, famotidine was similar in efficacy to cimetidine in the treatment of upper gastrointestinal bleeding and to ranitidine in the prevention of pulmonary aspiration of acid. In patients with Zollinger-Ellison syndrome, the potency and long duration of action of famotidine may confer an advantage over other H2-receptor antagonists--in individualised doses (mean 0.33 g/day) famotidine successfully controlled acid secretion for up to 72 months in 1 study of such patients. Accumulated clinical evidence confirms that famotidine is very well tolerated and is free of the antiandrogenic effects infrequently reported with cimetidine. Moreover, famotidine is not associated with altered hepatic metabolism of drugs. Thus, famotidine is an effective, well-tolerated alternative to cimetidine and ranitidine. Famotidine is also promising as maintenance therapy for preventing recurrence of duodenal ulcer and as initial or maintenance treatment of gastric hypersecretory disorders, but further clinical experience, particularly in the long term, is needed to define the relative efficacy and tolerability of famotidine in these indications.     

Lafutidine can improve the quality of gastric ulcer healing in humans: a randomized, controlled, multicenter trial

Improving the quality of ulcer healing (QOUH) is one of the valid methods of prevention of relapse of gastric ulcers. We investigated the effect of lafutidine on the QOUH of gastric ulcer compared with famotidine in a randomized, multi-centre controlled trial. Consecutive 80 patients with a gastric ulcer were randomly assigned to receive twice daily either lafutidine (10 mg) or famotidine (20 mg) for 12 weeks. Esophagogastroduodenoscopy was performed to examine the ulcer healing rate and rate of fl at type ulcer scars using dye-contrast. The gastric ulcer healing rate was 92.1% in the lafutidine group (35/38) and 94.7% in the famotidine group (36/38). The rate of flat-type ulcer scars was significantly higher in the lafutidine group (68.4%, 26/38) than in the famotidine group (42.1%, 16/38) (P = 0.021). In conclusion, the present study demonstrated that lafutidine, as compared to famotidine, yields a signifi cantly superior QOUH in patients with gastric ulcers in the clinical setting. Received and accepted 3 August 2006     

葡萄糖酸锌联合法莫替丁三联治疗幽门螺杆菌阳性消化性溃疡的疗效观察

目的观察葡萄糖酸锌联合法莫替丁三联治疗幽门螺杆菌(Hp)阳性消化性溃疡的疗效。方法对60例经胃镜证实有消化性溃疡并幽门螺杆菌感染患者,按就诊顺序随机分为实验组31例,对照组29例。两组均用法莫替丁、阿莫西林、克拉霉素三联治疗,两组治疗1周后均停服阿莫西林、克拉霉素,续用法莫替丁3周,4周为1个疗程。实验组在整个疗程联合用葡萄糖酸锌,而对照组不用。治疗期间,每周随访1次,每次记录腹痛、腹胀、返酸、嗳气、上腹部灼热感等症状及不良反应,并分别在治疗前及疗程结束后3d内由同一医生胃镜观察溃疡愈合程度及监测幽门螺杆菌根除率。结果溃疡愈合比较,两组完全愈合率、总愈合率比较差异均有统计学意义(P<0.05);幽门螺杆菌根除率比较,实验组高于对照组,差异有统计学意义(P<0.05),症状缓解及不良反应等比较,差异无统计学意义(P>0.05)。结论葡萄糖酸锌能增强法莫替丁三联治疗消化性溃疡的愈合,有抑制幽门螺杆菌作用,能提高其根除率。     

埃索美拉唑三联与奥美拉唑三联治疗Hp阳性十二指肠溃疡的对比研究

目的:比较埃索美拉唑三联与奥美拉唑三联疗法治疗幽门螺杆菌(Hp)阳性十二指肠球部溃疡的临床疗效。方法:将124例经内镜诊断并检测证实Hp阳性的十二指肠球部溃疡患者随机分为两组。埃索美拉唑组(62例):埃索美托唑20mg加阿莫西林lg加克拉霉素500mg,每日2次,共7天;奥美拉唑组(62例):奥美拉唑20mg加阿莫西林1g加克拉霉素500mg,每日2次,共7天。疗程结束4周后胃镜检查并检测Hp,观察腹痛缓解率、溃疡愈合率、Hp根除率及药物不良反应。结果:埃索美拉唑组第一天和第二天腹痛缓解率分别为35.8%和60.2%,高于奥美托唑组的16.5%和40.3%(P<0.05)。埃索美托唑组和奥美拉唑组溃疡愈合率分别为93.6%和89.5%,Hp根除率分别为87.9%和83.7%,差异无显著性(P>0.05)。两组药物不良反应少,有较好的安全性。结论:埃索美托唑三联疗法治疗Hp阳性的十二指肠溃疡安全有效。腹痛状缓解速度明显优于奥美拉唑三联疗法。     

Lansoprazole: A Comprehensive Review

Lansoprazole is the second member of the substituted benzimidazole class of antisecretory agents approved for use in the United States. These drugs decrease parietal cell acid secretion by inhibiting H⁺,K⁺-adenosine triphosphatase, the final step in the secretion of acid. Lansoprazole has been studied extensively for the short-term treatment of duodenal and gastric ulcers, reflux esophagitis, and Helicobacter pylori-positive peptic ulcer disease; long-term treatment of Zollinger-Ellison syndrome; and maintenance treatment of erosive esophagitis. A dosage of 30 mg/day produced higher healing rates and equivalent or faster relief of ulcer symptoms than ranitidine or famotidine in patients with duodenal or gastric ulcers and reflux esophagitis. Compared with omeprazole 20 mg/day, that dosage provided faster epigastric pain relief in these patients after 1 week, although healing rates for the two agents were equivalent at 4 and 8 weeks. In patients with peptic ulcer refractory to 8-week therapy with histamine₂-receptor antagonists, healing rates were not significantly different between lansoprazole and omeprazole. In patients with Zollinger-Ellison syndrome, lansoprazole was superior to histamine₂-receptor antagonists and was similar in efficacy, safety, and duration of action to omeprazole. Combinations of lansoprazole or omeprazole with one or two antibiotics produced equivalent eradication of H. pylori. In clinical trials, lansoprazole was well tolerated, with frequency of adverse effects similar to that reported with ranitidine, famotidine, and omeprazole.     

Omeprazole versus famotidine in the healing and relapse of duodenal ulcer

Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2–4 weeks in a double-blind parallel group clinical trial. Healing rates were higher with omeprazole in comparison with famotidine after 2 weeks (77%vs. 40%, P < 0.001) and 4 weeks (93%vs. 80%, P= 0.2) of treatment. Assessment of daily diary cards completed by all patients revealed that omeprazole rapidly relieved ulcer-related day pain and nocturnal pain in comparison to famotidine. Treatment with omeprazole for 2 weeks was also associated with lower cumulative antacid intake (P < 0.05) and reduced absenteeism from work. Helicobacter pylori infection was present in all patients and remained unaffected by treatment with either of the drugs. None of the drugs produced any significant adverse effects. During 6 months follow-up of all the patients after ulcer healing (without maintenance therapy), ulcer relapse was seen in 40% of omeprazole- and 37% of famotidine-treated patients (P > 0.1). The duration of ulcer-free period following initial healing of ulcer was also similar in both the groups (median time: 22 weeks for omeprazole, 21 weeks for famotidine). We conclude that omeprazole is superior to famotidine in rapidly healing duodenal ulcers and achieving more rapid pain relief, but does not influence subsequent ulcer relapse.     

西沙比利治疗老年人功能性消化不良的疗效

607例门诊老年功能性消化不良患者随机分为治疗组和对照组.治疗组(317例)中po西沙比利5mp tid×4wk;对照组(290例)po多福立酮10mgtid×4wk.结果:西沙比利对餐后饱胀、上腹胀满、恶心及呕吐等症状的缓解作用明显优于多潘立酮(P<0.01).治疗组总有效率为86.1%,对照组为77.6%,差异有显著性.西沙比利的主要不良反应为腹泻、肠鸣和腹痛,但患者可以耐受.结果表明西沙比利对老年人功能性消化不良有良好的疗效.     

法莫替丁与西咪替丁治疗消化性溃疡各20例的近期疗效比较

本文观察胃镜确诊的十二指肠溃疡及胃溃疡患者共40例,随机分为2组:即服法莫替丁的治疗组20例与服西咪替丁的对照组20例,均以6wk为一个疗程。疗程结束后再由胃镜复查,其溃疡愈合率在治疗组与对照组分别为90％与65％,差异显著(P<0.01)。观察结果,法莫替丁治疗消化性溃疡的近期疗效高,对上腹部疼痛缓解较西咪替丁显著,不良反应少。